Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04906993 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

StatusActive, Not Recruiting
PhasePhase 3
Started2021-07-23
View on ClinicalTrials.gov ↗

Amendment history

2025-09-08
Study Status v3
Primary completion dateestimated 2025-04→confirmed 2025-06-10
Completion date2025-04→2027-05-31
2024-12-30
Enrolling by Invitation→Active, Not Recruiting Study Status, Study Design v2
Trial statusEnrolling by Invitation→Active, Not Recruiting
Primary completion date2022-12-31→2025-04
Completion date2023-05-31→2025-04
Enrollment targetestimated 440→confirmed 443
2021-12-12
Not Yet Recruiting→Enrolling by Invitation Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Enrolling by Invitation
Start dateestimated 2021-06-15→confirmed 2021-07-23
Study sites0→1
2021-05-26
Original filing
This study is a randomized, open-label, controlled, multi-center Phase III clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate versus platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer. All enrolled patients will be randomly divided into 2 groups and continuously treated until any event that meets the criteria for end of the clinical trial.
Trial Details
NCT Number NCT04906993
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Cervical Cancer
Enrollment 443 participants
Start Date 2021-07-23
Primary Completion 2025-06-10 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-09